mycophenolic-acid and Gastroesophageal-Reflux

mycophenolic-acid has been researched along with Gastroesophageal-Reflux* in 2 studies

Reviews

1 review(s) available for mycophenolic-acid and Gastroesophageal-Reflux

ArticleYear
Interstitial lung disease in systemic sclerosis.
    Autoimmunity reviews, 2011, Volume: 10, Issue:5

    Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies. ILD develops in up to 75% of patients with SSc overall. However, SSc-ILD evolves to end-stage respiratory insufficiency in only a few patients. Initial pulmonary function tests (PFT) with measurement of carbon monoxide diffusing capacity, together with high-resolution computed tomography, allows for early diagnosis of SSc-ILD, before the occurrence of dyspnea. Unlike idiopathic ILD, SSc-ILD corresponds to non-specific interstitial pneumonia in most cases, whereas usual interstitial pneumonia is less frequently encountered. Therefore, the prognosis of SSc-ILD is better than that for idiopathic ILD. Nevertheless, ILD represents one of the two main causes of death in SSc patients. To detect SSc-ILD early, PFT must be repeated regularly, every 6 months to 1 year, depending on disease worsening. Conversely, broncho-alveolar lavage is not needed to evaluate disease activity in SSc-ILD but may be of help in diagnosing opportunistic infection. The treatment of SSc-ILD is not well established. Cyclophosphamide, which has been used for 20 years, has recently been evaluated in two prospective randomized studies that failed to demonstrate a major benefit for lung function. Open studies reported mycophenolate mofetil, azathioprine and rituximab as alternatives to cyclophosphamide. On failure of immunosuppressive agent treatment, lung transplantation can be proposed in the absence of other major organ involvement or severe gastro-esophageal reflux.

    Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Azathioprine; Contraindications; Cyclophosphamide; DNA Topoisomerases, Type I; Four-Dimensional Computed Tomography; Gastroesophageal Reflux; Humans; Immunosuppressive Agents; Lung; Lung Diseases, Interstitial; Lung Transplantation; Mycophenolic Acid; Prognosis; Pulmonary Fibrosis; Randomized Controlled Trials as Topic; Respiratory Function Tests; Rituximab; Scleroderma, Systemic

2011

Trials

1 trial(s) available for mycophenolic-acid and Gastroesophageal-Reflux

ArticleYear
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
    Chest, 2017, Volume: 151, Issue:4

    Cough is a common symptom of scleroderma-related interstitial lung disease (SSc-ILD), but its relationship to other characteristics of SSc-ILD, impact on cough-specific quality of life (QoL), and response to therapy for SSc-ILD have not been well studied.. We investigated frequent cough (FC) in patients with SSc-ILD (N = 142) enrolled in the Scleroderma Lung Study II, a randomized controlled trial comparing mycophenolate mofetil (MMF) and oral cyclophosphamide (CYC) as treatments for interstitial lung disease (ILD). We determined the impact of FC on QoL (Leicester Cough Questionnaire [LCQ]), evaluated the change in FC in response to treatment for SSc-ILD, and examined the relationship between gastroesophageal reflux disease (GERD) and cough during the trial.. Study participants who reported FC at baseline (61.3%) reported significantly more dyspnea, exhibited more extensive ILD on high-resolution CT, had a lower diffusing capacity for carbon monoxide, and reported more GERD symptoms than did those without FC. Cough-specific QoL was modestly impaired in patients with FC (total LCQ score, 15.4 ± 3.7; normal range, 3-21 [higher scores indicate worse QoL]). The proportion of patients with FC at baseline declined by 44% and 41% over 2 years in the CYC and MMF treatment arms, respectively, and this decline was significantly related to changes in GERD and ILD severity.. FC occurs commonly in SSc-ILD, correlates with both the presence and severity of GERD and ILD at baseline, and declines in parallel with improvements in both ILD and GERD over a 2-year course of therapy. Frequent cough might serve as a useful surrogate marker of treatment response in SSc-ILD trials.. ClinicalTrials.gov; No.: NCT00883129; URL: www.clinicaltrials.gov.

    Topics: Cough; Cyclophosphamide; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Quality of Life; Respiratory Function Tests; Scleroderma, Systemic; Severity of Illness Index; Treatment Outcome

2017